Tdp-43 Biomarker
Tdp-43 Biomarker - Related Videos
13:31
Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
0 Views •
Cited by 17 •
2015
Using atomic force microscopy in combination with biopanning technology we created a negative and positive biopanning system to acquire antibodies against disease-specific protein variants present in any biological material, even at low concentrations. We were successful in obtaining antibodies to TDP-43 protein variants involved in Amyotrophic Lateral Sclerosis.
07:07
Measuring Glucose Uptake in Drosophila Models of TDP-43 Proteinopathy
0 Views •
Cited by 3 •
2021
Glucose uptake is increased in Drosophila motor neurons affected by TAR DNA binding protein (TDP-43) proteinopathy, as indicated by a FRET-based, genetically encoded glucose sensor.
07:14
Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae
0 Views •
2022
We describe a protocol to induce phase transition of TAR DNA-binding protein 43 (TDP-43) by light in the spinal motor neurons using zebrafish as a model.
08:29
Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD
0 Views •
Cited by 29 •
2012
We describe a rat model of post traumatic stress disorder (PTSD) that reveals the persistent alterations in neuroendocrine function and the delayed long-term, exaggerated fear response, characteristic of PTSD patients. The animal model and methods described here are useful for correlating biomarkers in brain nuclei, which are mechanistic but cannot be measured in patients, with biomarkers in peripheral white blood cells, which can.
09:20
Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption
0 Views •
Cited by 6 •
2019
Here, we present a mechanics-based protocol to disrupt the gap junction connexin 43 and measure the subsequent impact this has on endothelial biomechanics via observation of tractions and intercellular stresses.
FAQs
A key change is the movement of TDP-43 from the nucleus into the cytoplasm, where abnormal inclusions can accumulate. This redistribution matters because TDP-43 normally participates in cellular functions linked to RNA processing. Its displacement, together with cytoplasmic accumulation, provides a mechanistic connection between the pathology detected by a TDP-43 biomarker and disrupted neuronal biology.
These molecular changes help characterize the abnormal TDP-43 material found in affected neurons. Phosphorylated and ubiquitinated forms, along with fragmented protein, distinguish disease-associated inclusions from a simple change in protein location. Measuring or identifying these features can therefore provide more biologically informative evidence than assessing TDP-43 abundance without considering its pathological form.
They may help distinguish conditions that share clinical or pathological features, including amyotrophic lateral sclerosis and frontotemporal dementia. The value comes from relating TDP-43-associated signals to disease biology rather than treating them as a standalone label. Such information can support characterization of overlapping disorders, although the overview presents these biomarkers as tools under development rather than definitive replacements for broader assessment.
Brain-tissue assessment examines the cellular pathology directly, including abnormal localization and inclusions in affected neurons. Fluid-based approaches instead seek disease-related TDP-43 signals in cerebrospinal fluid or blood. This distinction gives researchers complementary ways to study the same disease biology: tissue analysis provides pathological context, while developing fluid assays may make biomarker assessment more accessible during investigation.
Patient stratification means grouping individuals according to shared biological characteristics. TDP-43 biomarker findings may help identify people whose disease involves this pathology, allowing studies to characterize clinically overlapping populations more precisely. In neuroscience research, that distinction can improve comparisons among participants and support evaluation of therapies aimed at disease processes associated with abnormal TDP-43.
They may provide biological measures for selecting participants and evaluating whether a treatment is relevant to TDP-43-associated disease mechanisms. Repeated assessment, particularly through developing cerebrospinal-fluid or blood assays, could support monitoring of disease-related signals during therapy research. The intended outcome is better alignment between a targeted intervention, the patients receiving it, and measurable pathological biology.